Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) ...
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...
Hosted on MSN23d
Novel therapy being tested for treating rheumatic fever"Subcutaneous injections are less painful than intramuscular ... of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease, mBio (2025). DOI: 10.1128/mbio.
“Subcutaneous injections are less painful than intramuscular penicillin ... 2 therapy halts the progression of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease’ ...
60 SD rats were enrolled in the LIPUS function assay and were ... 2021), the Force + GsMTx4 and Force + GsMTx4 + LIPUS groups received a subcutaneous injection behind the neck of the Piezo1 inhibitor, ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery, ...
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback